Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mayan Gilboa

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2022
The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 InfectionNoam Barda, Michal Canetti, Mayan Gilboa, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|July 29, 2022
COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022Limor Kliker, Neta Zuckerman, Nofar Atari, et al.
Viruses|January 8, 2025
Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort StudyGili Joseph, Ili Margalit, Yael Weiss-Ottolenghi, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 30, 2022
Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022Noam Barda, Michal Canetti, Mayan Gilboa, et al.
Nature Immunology|May 9, 2022
Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine doseYaniv Lustig, Tal Gonen, Lilac Meltzer, et al.
Nature Communications|December 13, 2022
Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-upMichal Canetti, Noam Barda, Mayan Gilboa, et al.
The Journal of Infectious Diseases|December 1, 2021
Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World ExperienceMayan Gilboa, Michal Mandelboim, Victoria Indenbaum, et al.
JAMA Network Open|May 23, 2023
Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in IsraelMayan Gilboa, Tal Gonen, Noam Barda, et al.
The Lancet. Microbe|March 24, 2023
Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort studyGili Regev-Yochay, Yaniv Lustig, Gili Joseph, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2025
Effectiveness of imipenem-relebactam for multidrug-resistant <i>Pseudomonas aeruginosa</i> in pneumonia and bloodstream infections in the United States (MIRAGE)Walaiporn Wangchinda, Janet Y Wu, Lilian M Abbo, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2022
The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 InfectionNoam Barda, Michal Canetti, Mayan Gilboa, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|July 29, 2022
COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022Limor Kliker, Neta Zuckerman, Nofar Atari, et al.
Viruses|January 8, 2025
Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort StudyGili Joseph, Ili Margalit, Yael Weiss-Ottolenghi, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 30, 2022
Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022Noam Barda, Michal Canetti, Mayan Gilboa, et al.
Nature Immunology|May 9, 2022
Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine doseYaniv Lustig, Tal Gonen, Lilac Meltzer, et al.
Nature Communications|December 13, 2022
Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-upMichal Canetti, Noam Barda, Mayan Gilboa, et al.
The Journal of Infectious Diseases|December 1, 2021
Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World ExperienceMayan Gilboa, Michal Mandelboim, Victoria Indenbaum, et al.
JAMA Network Open|May 23, 2023
Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in IsraelMayan Gilboa, Tal Gonen, Noam Barda, et al.
The Lancet. Microbe|March 24, 2023
Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort studyGili Regev-Yochay, Yaniv Lustig, Gili Joseph, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2025
Effectiveness of imipenem-relebactam for multidrug-resistant <i>Pseudomonas aeruginosa</i> in pneumonia and bloodstream infections in the United States (MIRAGE)Walaiporn Wangchinda, Janet Y Wu, Lilian M Abbo, et al.
Pageof 3